Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Partnerships Are Key To Foundation Medicine's Success

Executive Summary

Since receiving approval for the first broad-panel diagnostic test as a combination product to detect cancer, Foundation Medicine has ramped up its partnerships with pharmaceutical companies and other stakeholders. The company expects to receive a similar approval for a broad-panel liquid biopsy genomic test in the first half of 2020.

You may also be interested in...



FDA Approves Foundation Medicine Liquid Biopsy Test As Companion Diagnostic For Lynparza

The US FDA expanded the use of FoundationOne Liquid CDx as a companion diagnostic for certain prostate cancer patients eligible for treatment with olaparib.

Freenome Raises $270M In Series C, Accelerates Trial For Colorectal Cancer Test

Funding will accelerate an FDA registrational study of the company's first liquid biopsy product, as competition increases in early cancer detection.     

December 2019 Approvals Snapshot: Abbott Earns New Approval For CentriMag Circulatory Support System

December’s new medical device approvals include the FDA approval of Abbott Laboratories’ CentriMag circulatory support system for postcardiotomy patients, MicroVention’s FRED system for wide-necked intracranial aneurysms and an expanded indication for Foundation Medicine’s FoundationOne CDx cancer-drug companion diagnostic.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT126067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel